A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF bispecific heads into the ASCO annual meeting with a prestigious spot on the plenary session.